BioPharma Resources

Drug Trial Radar · NCT07626437

Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults

A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult Participants

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

May 8, 2026

Primary completion

Jun 28, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.

Conditions

  • Common Cold/Flu
  • Nasal Congestion
  • Nasal Obstruction

Interventions

  • dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mgDrug

    The differential of this study is the dosages and reduction of doses per day.

  • dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mgDrug

    The differential of this intervention is the dosages

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who show improvement in symptoms of nasal obstruction and/or congestionTime frame: 3 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Anima de Extensão Universitária - Unibh

    Belo Horizonte, Minas Gerais, Brazil · Not yet recruiting

  • Centro de Ensino Superior de Vespasiano

    Vespasiano, Minas Gerais, Brazil · Not yet recruiting

  • Norte Pesquisa Clínica

    Belém, Pará, Brazil · Not yet recruiting

  • Apec Sociedade Potiguar de Educação E Cultura

    Natal, Rio Grande do Norte, Brazil · Not yet recruiting

  • Instituto Anima de Extensão Universitária - Unisul

    Palhoça, Santa Catarina, Brazil · Not yet recruiting

  • Husf Hospital Universitário São Francisco Na Providência de Deus

    Bragança Paulista, São Paulo, Brazil · Not yet recruiting

  • Newdata Clinical Research - Parkmed

    Bragança Paulista, São Paulo, Brazil · Not yet recruiting

  • Cipes Centro Internacional de Pesquisa Clínica

    São José dos Campos, São Paulo, Brazil · Not yet recruiting

  • Synvia Clinical

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Iscp Sociedade Educacional

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Rdss Ricardo Diaz Scientific Solution

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • A2Z Clinical Centro de Pesquisa Clínica

    Valinhos, São Paulo, Brazil · Not yet recruiting

  • Fundação de Beneficência Hospital de Cirurgia

    Aracaju, Sergipe, Brazil · Not yet recruiting

  • Newdata Clinical Research

    Aracaju, Sergipe, Brazil · Recruiting

  • Associação Aracajuana Hospital Santa Isabel

    Aracaju, Sergipe, Brazil · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.